Researchers are studying people with familial early-onset Alzheimer's disease to gain insight into the disease, NPR reports.
In PNAS this week: genetic variants linked to response to food ads, effects of MECP2 mutations in Rett syndrome, and more.
Response to a low toxicity drug called decitabine was most pronounced in acute myeloid leukemia and myelodysplastic syndrome cases with TP53 mutations.
The large-scale study is designed to advance personalized medicine for pancreatic cancer to help meet the organization's goal of doubling patient survival rates by 2020.
The centers will support the NCI's Genomic Data Analysis Network, which is tasked with creating tools and strategies to study large-scale genomics data.
The team has received around $900,000 in National Cancer Institute funding to develop new capabilities for CIVIC, improve curation, and engage with the community.
The funding will be used to support Appistry's operations and engineering efforts, including the continued development of its GenomePilot DNA data-analysis software.
A genomic look at estrogen receptor-positive tumors before and after neoadjuvant aromatase inhibitor therapy suggests ongoing molecular monitoring may be needed.
The researchers also developed a mouse model of the mutation using CRISPR/Cas9 genome engineering to examine its effects.
The partners have integrated WashU's VarScan with Appistry's GenomePilot, which provides preconfigured workflows for clinical NGS.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.